《新股消息》麥迪衛康再遞上市申請 中期盈轉虧
內地心腦血管疾病綜合醫療營銷商麥迪衛康第三度提交上市申請,獨家保薦人光銀國際。
初步招股文件顯示,麥迪衛康主要提供醫學會議服務、患者教育及自測服務、營銷戰略和諮詢服務、CRO服務以及互聯網醫院服務,疾病領域覆蓋心腦血管疾病、如糖尿病及呼吸道疾病。
截至今年6月底止中期,麥迪衛康收入錄約1.39億元人民幣,按年減少14.3%,期內盈轉虧,蝕400.7萬元人民幣,對比2019年同期溢利錄207.5萬元人民幣。公司解釋,期內轉盈為虧是由於疫情爆發令醫學會議產生的收入大幅下跌。
預期集資所得將用於拓展客戶群及患者群、開發互聯網醫院服務、擴充CRO服務及一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.